Stock Screener App

무료 -

6.04

5.04% +0.29

Lipocine Inc (LPCN)

개요 뉴스 가격 이력 Financials 토론 예측 주식 분할

Lipocine Inc 주식(LPCN)의 최신 뉴스

Long Term Trading Analysis for (LPCN) - Stock Traders Daily

Stock Traders Daily

Why Lipocine Inc.'s (NASDAQ:LPCN) CEO Pay Matters To You - Yahoo New Zealand News

Yahoo New Zealand News

StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) - Defense World

Is Lipocine Inc.'s (NASDAQ:LPCN) Balance Sheet Strong Enough To Weather A Storm? - Yahoo Lifestyle Australia

Yahoo Lifestyle Australia

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 - PR Newswire

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress ... - BioSpace

Lipocine Inc expected to post a loss of 68 cents a share - Earnings Preview - XM

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 - PR Newswire

Lipocine reports positive results from obesity treatment trial - Investing.com

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis - PR Newswire

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 - PR Newswire

Lipocine to Present at 36th Annual Roth Conference – Company Announcement - FT.com - Financial Times

Financial Times

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 - PR Newswire

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals - PR Newswire

Lipocine licenses Tlando testosterone therapy to Verity Pharma (NASDAQ:LPCN) - Seeking Alpha

Lipocine to Present at Biotech Showcase 2024 - PR Newswire

Postpartum Depression Market to Exhibit Positive Growth During the Forecast Period (2023–2032), Predicts ... - Yahoo Finance

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 - PR Newswire

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 - PR Newswire

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression - PR Newswire

Lipocine gears up for two pivotal trials in 2023/2024 - Clinical Trials Arena

Clinical Trials Arena

LPCN: 1148 Shows Muscle Loss Reversal - Yahoo Finance

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis - PR Newswire

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 - PR Newswire

LPCN: 1154 Results Illuminate Accelerated Pathway - Yahoo Finance

Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral ... - PR Newswire

Lipocine doses first subject in clinical bridge study of LPCN 1154 - Clinical Trials Arena

Clinical Trials Arena

Lipocine Shifts Pipeline Focus to CNS Disorders (Updated) - BioSpace

FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment - PR Newswire

FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by ... - BioSpace

Antares, Lipocine expand testosterone therapy offerings with FDA nod for a new, oral med for hypogonadism - FiercePharma

LIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER ... - PR Newswire

Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH - PR Newswire

Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO® - PR Newswire

LPCN: Lipocine's LiFT Results: A Comparison with Peers - Yahoo Finance

FDA Finally Gives Tentative Approval To Lipocine's Oral Testosterone Replacement Therapy - RTTNews

Lipocine Announces Regulatory Path Forward for TLANDO™ Resubmission - PR Newswire

Mid-Day Market Update: Carbonite Jumps Following Acquisition News; Lipocine Shares Plummet - ASLAN Pharma - Benzinga

Is Lipocine Inc.'s (NASDAQ:LPCN) Balance Sheet Strong Enough To Weather A Storm? - Yahoo Lifestyle Australia

Yahoo Lifestyle Australia

Lipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction ... - PR Newswire

LPCN: Androgen Therapy in NASH: A Comprehensive Approach - Zacks Small Cap Research

Zacks Small Cap Research

Lipocine Announces Settlement of Securities Class Action Lawsuit - PR Newswire

Lipocine Announces $10 Mln Loan And Security Agreement With Silicon Valley Bank - Reuters.com

Aytu's Natesto Is Set To Take The $3.8 Billion TRT Market While Lipocine And Clarus Therapeutics Fail (NASDAQ:AYTU) - Seeking Alpha

Lipocine Inc (LPCN) Fails to Convince FDA Advisory Committee of TLANDO's Merit; Shares Decline Over 50% - Yahoo Finance

Buzz Stocks: TESARO Inc, Lipocine Inc, and Energy Transfer Equity LP - Schaeffers Research

Schaeffers Research

Lipocine, Inc. (LPCN) Stock | Approval from FDA for New Drug Application - Warrior Trading News

Warrior Trading News

Oral Testosterone Pill Could Make Lipocine Worth Substantially More - 24/7 Wall St.

Lipocine Gets Orphan Designation For Preterm Birth Drug (NASDAQ:LPCN) - Seeking Alpha

$77.56

0.77%

$149.40

1.20%

$29.98

1.11%

$172.85

1.06%

$365.81

2.87%

$90.61

2.55%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기